A Phase 2, Open-Label, Randomized Trial Evaluating the Impact of Enhanced Versus Standard Dermatologic Management on Selected Dermatologic Adverse Events Among Patients With Locally Advanced or Metastatic EGFR-Mutated NSCLC Treated First-Line With Amivantamab + Lazertinib

This study looks at the best ways to manage skin side effects, such as rashes or acne, that can happen when taking lung cancer medications called amivantamab and lazertinib. By testing 'enhanced' skin care plans, the researchers hope to find better ways to keep your skin healthy and comfortable during your cancer treatment.

This study is for people with advanced, non-small cell lung cancer that has a specific genetic change called an EGFR mutation. Participants must be starting their first treatment for this advanced cancer and be in overall good health, aside from their cancer diagnosis.

You will receive standard lung cancer treatment while following a specialized skin care plan that may include creams, cleansers, or medications to prevent or treat skin irritation. The medical team will monitor your skin closely and adjust your care routine based on how your body reacts to the treatment.

The study is currently active but is no longer looking for new participants. Locations include clinics in Chandler, Arizona, and Duarte and Fullerton, California.